Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Adial Pharmaceuticals Inc

Healthcare US ADIL

2.98USD
0.00(0%)

Last update at 2026-06-12T20:28:00Z

Day Range

2.523.14
LowHigh

52 Week Range

1.5421.38
LowHigh

Fundamentals

  • Previous Close 2.98
  • Market Cap2.27M
  • Volume850141
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-7.79890M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-11.93

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -7.97717M -13.19745M -7.00189M -12.73192M -19.51740M
Minority interest - - - - -
Net income -7.97717M -13.19745M -7.00189M -12.73142M -19.42333M
Selling general administrative 5.18M 5.06M 5.62M 9.14M 9.34M
Selling and marketing expenses - - 0.00056M - -
Gross profit -0.00056M -0.00056M -0.00056M - -
Reconciled depreciation 0.00056M 0.00056M 0.06M 0.06M 0.06M
Ebit -7.80003M -8.28446M -7.00189M -13.31713M -19.28872M
Ebitda -7.79946M -8.28389M -7.00133M -13.77863M -15.85511M
Depreciation and amortization 0.00056M 0.00056M 0.00056M -0.46150M 3.43M
Non operating income net other - - - - -
Operating income -7.79946M -8.28446M -6.88795M -13.31713M -19.28872M
Other operating expenses 7.80M 8.28M 6.89M 13.32M 17.74M
Interest expense - - - 0.59M 3.61M
Tax provision - 0.00000M -0.00050M -0.00050M -0.09408M
Interest income 0.15M 0.18M 0.11M 0.06M 0.00654M
Net interest income 0.15M 0.18M 0.11M 0.06M 0.00654M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - -1.87855M -0.00050M -0.09408M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 7.80M 8.28M 6.89M 13.32M 17.74M
Cost of revenue 0.00056M 0.00056M 0.00056M - -
Total other income expense net -0.17771M -4.91299M -0.11394M 0.59M -0.22868M
Discontinued operations - - - - -
Net income from continuing ops -7.97717M -13.19745M -9.58241M -12.73142M -19.42333M
Net income applicable to common shares - - - - -19.42333M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 6.67M 5.04M 4.74M 5.73M 7.47M
Intangible assets 0.00278M 0.00335M 0.00391M 0.46M 0.46M
Earning assets - - - - -
Other current assets 0.26M 0.31M 0.37M 0.35M 0.39M
Total liab 1.40M 0.98M 0.65M 2.46M 3.97M
Total stockholder equity 5.28M 4.07M 4.08M 3.28M 3.51M
Deferred long term liab - - - - -
Other current liab 0.74M 0.73M 0.53M 1.34M 0.00968M
Common stock 0.00111M 0.00647M 0.00166M 0.03M 0.02M
Capital stock 0.00111M 0.00647M - 0.03M 0.02M
Retained earnings -89.97249M -81.99532M -68.79787M -63.67453M -50.94311M
Other liab - - - - 1.04M
Good will - - - 0.25M 0.25M
Other assets - - - - -
Cash 5.88M 3.75M 2.83M 4.00M 6.06M
Cash and equivalents - - - - -
Total current liabilities 1.40M 0.98M 0.65M 1.79M 2.72M
Current deferred revenue - - - - 2.38M
Net debt -5.88122M -3.75053M -2.82708M -3.79442M -5.80521M
Short term debt - - - 0.06M 0.05M
Short long term debt - - - - -
Short long term debt total - - - 0.21M 0.26M
Other stockholder equity 95.25M 86.06M 72.88M 66.92M 54.43M
Property plant equipment - - - - 0.30M
Total current assets 6.18M 4.06M 3.20M 4.78M 6.46M
Long term investments 0.49M 0.98M - - -
Net tangible assets - - - - 2.80M
Short term investments - - - - -
Net receivables 0.04M - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 0.66M 0.25M 0.13M 0.39M 0.29M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.49M - 1.53M 0.65M 0.70M
Deferred long term asset charges - - - - -
Non current assets total 0.49M 0.99M 1.54M 0.95M 1.01M
Capital lease obligations - - - 0.21M 0.26M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 0.00000M 1.15M 0.00000M -0.03402M
Change to liabilities - - - - -0.35377M
Total cashflows from investing activities 0.15M - 1.50M - -0.03402M
Net borrowings - - - - -
Total cash from financing activities 8.47M 7.85M 4.13M 9.13M 13.64M
Change to operating activities - - - - 1.46M
Net income -7.97717M -13.19745M -7.00189M -12.73142M -19.42333M
Change in cash 2.13M 0.92M -1.17471M -2.06038M 1.66M
Begin period cash flow 3.75M 2.83M 4.00M 6.06M 4.40M
End period cash flow 5.88M 3.75M 2.83M 4.00M 6.06M
Total cash from operating activities -6.49260M -6.92231M -6.80681M -11.18599M -11.94943M
Issuance of capital stock 3.66M 4.02M 0.75M 9.12M 11.75M
Depreciation 0.00056M 0.00056M 0.00056M 0.06M 0.06M
Other cashflows from investing activities 0.15M - 1.50M - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - -0.00166M - -
Other cashflows from financing activities 8.47M 3.82M 4.13M 0.00186M 1.89M
Change to netincome - - - - 5.95M
Capital expenditures 0.00000M 0.00000M 6.81M 0.00000M 0.06M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.47M 0.39M -0.79421M -1.36706M 1.46M
Stock based compensation 0.68M 0.80M 1.75M 3.37M 4.24M
Other non cash items 0.34M 5.09M -0.75766M -0.52200M 1.81M
Free cash flow -6.49260M -6.92231M -6.80681M -11.18599M -12.01403M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
ADIL
Adial Pharmaceuticals Inc		 - -% 2.98 - - - 0.44 -0.4912
NVO
Novo Nordisk A/S		 -0.08 0.18% 43.88 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.99 4.74% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.115 0.03% 444.93 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 0.66 0.11% 612.14 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.

Adial Pharmaceuticals Inc

4870 Sadler Road, Glen Allen, VA, United States, 23060

Key Executives

Name Title Year Born
Mr. Cary John Claiborne MBA CEO, Pres & Director 1961
Mr. Joseph A. M. Truluck M.B.A., MBA CFO, Treasurer & Sec. 1978
Dr. Bankole A. Johnson DSc, FRCPsych, M.D., M.Phil, Ph.D. Founder & Chief Medical Officer 1960
Mr. John R. Martin J.D. Gen. Counsel NA
Mr. Alex Lugovoy Chief Bus. Officer NA
Dr. Jack W. Reich Ph.D. Head of Regulatory 1949
Mr. Mark H. Peikin Chief Strategy Officer & Chief Devel. Officer NA
Mr. Lawrence Goldman CPA Controller 1956
Ms. Catherine Fratila Controller NA
Mr. Cary John Claiborne MBA CEO, President & Director 1961

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.